In a Korean study, there was a significant trend of increased risk of reactivation with increasing intensity of therapy, with hazard ratio of 1.0 for local ablation therapy, 2.45 for TACE (using Adriamycin), 4.19 for TACE (using cisplatin), and 10.17 for TACE (using cisplatin) with RT [ 26 ].
← all excerpts
Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.
1
—
—